Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today ...
Raymond James Sticks to Its Buy Rating for Thermo Fisher (TMO)
Raymond James analyst Andrew Cooper maintained a Buy rating on Thermo Fisher (TMO – Research Report) today and set a price target of $667.00.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Quest Diagnostics (DGX) and Thermo Fisher (TMO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Quest Diagnostics (DGX – ...
Is Thermo Fisher Scientific (TMO) the Best Cancer Stock to Buy According to Hedge Funds?
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
The Armenian Reporter1d
Best Industrial Stocks To Consider – January 30th
Tesla, Broadcom, Vistra, Micron Technology, Thermo Fisher Scientific, Constellation Energy, and Vertiv are the seven ...
Thermo Fisher Scientific Inc. stock falls Friday, underperforms market
Shares of Thermo Fisher Scientific Inc. TMO slid 1.48% to $597.75 Friday, on what proved to be an all-around dismal trading ...
Analyst Expectations For Thermo Fisher Scientific's Future
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $654.0, with a high estimate of $680.00 and a low estimate of $605.00. Experiencing a 1.36% ...
Thermo Fisher Scientific Gaps Up And Nears A Buy Point On Strong Earnings Beat
Shares of Thermo Fisher Scientific surged Thursday after the life sciences titan beat Wall Street's fourth-quarter expectations.
Thermo Fisher sees robust 2025 profit on improved demand for its tools and services
Thermo Fisher Scientific on Thursday forecast annual profit above Wall Street estimates, banking on improved demand for its products and services used in developing therapies, sending its shares up 6.